multiple-myeloma

Documents about multiple-myeloma

• Common Safety Follow-up Trial of Tecemotide (L-BLP25)#426648ClinicalTrials.gov
• Two Cycles of PAD Combination by AHCT in MM#830904ClinicalTrials.gov
• A Survey on NINLARO Risk Management Plan (RMP) Material Utilization Among Pharmacists in Japan#856907ClinicalTrials.gov
• Exploratory Study on POL6326 in Stem Cell Mobilization#859184ClinicalTrials.gov
• Collection of Samples and Clinical Data From Patients With Amyloid Diseases#865224ClinicalTrials.gov
• Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab#870283ClinicalTrials.gov
• Real-World Mapping Antithrombotic Regimens in MM Patients on Treatment#885242ClinicalTrials.gov
• A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life#900339ClinicalTrials.gov
• A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant#847346ClinicalTrials.gov
• Multiple Myeloma is a Hematologic Malignancy Characterized by the Accumulation of Malignant Plasma Cells in the Bone Marrow. Despite Advances in Treatment, Many Patients Experience Disease Relapse. Bispecific Antibodies Offer an Innovative Therapeutic Approach, But Approximately 30%-40% of Patients#801150ClinicalTrials.gov
• An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem Cells#812479ClinicalTrials.gov
• Development of an Intervention Integrating Procedures Combining Hypnosis and Virtual Reality in the Support of Patients with Hematological Cancer#863430ClinicalTrials.gov
• Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma#294454Gestión del Repositorio Documental de la Universidad de Salamanca
• Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant#180403ClinicalTrials.gov
• MDM2 Drives Proteasome Inhibitor Resistance and Represents a TP53-Independent Therapeutic Vulnerability in Multiple Myeloma#185677IRIS
• Clinical and biological implications of TP53 abnormalities in relapsed/refractory multiple myeloma: the DEDALO study#308482IRIS
• Bone marrow breakout lesions act as key sites for tumor-immune cell diversification in multiple myeloma#331298PubMed Central
• Missed opportunities to promote flourishing in cancer care: a brief examination of multiple myeloma.#358122NCBI PubMed Central
• A Multistakeholder Qualitative Analysis of Barriers to Autologous Stem Cell Transplantation for Multiple Myeloma.#360481NCBI PubMed Central
• Machine Learning‐Derived Immune Gene Signature Predicts Prognosis and Therapeutic Vulnerabilities in Multiple Myeloma.#666135NCBI PubMed Central
• Nanomedicine-Empowered CAR-T Therapy for Multiple Myeloma: Toward Programmable, Durable, and Precision Immunotherapy.#666143NCBI PubMed Central
• Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Hematological Malignancy#807312ClinicalTrials.gov
• Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma#810836ClinicalTrials.gov
• Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone#830760ClinicalTrials.gov
• Identification of Occupational Exposures in Acute Hematologic Malignancy#839841ClinicalTrials.gov
• A Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone (MEL-VTD)#904196ClinicalTrials.gov
• PDD vs PAD to Treat Initially Diagnosed MM#911632ClinicalTrials.gov
• Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y002##978963ClinicalTrials.gov
• Iceland Screens, Treats or Prevents Multiple Myeloma#991945ClinicalTrials.gov
• Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma#314327ClinicalTrials.gov
• Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation#887574ClinicalTrials.gov
• A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant#904981ClinicalTrials.gov
• Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)#869738ClinicalTrials.gov
• A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)#909057ClinicalTrials.gov
• A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma#909622ClinicalTrials.gov
• Investigación del patrón de eliminación de la inmunoglobulina monoclonal mediante espectrometría de masas en pacientes con mieloma múltiple#424903Gestión del Repositorio Documental de la Universidad de Salamanca
• Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia#904890ClinicalTrials.gov
• Analyse exploratoire des stratégies antisens innovantes dans le traitement des maladies du lymphocyte B et du plasmocyte#643238HAL (France)
• Characteristic Patients with Multiple Myeloma at Dr. Kariadi Hospital Semarang#930390Acta Interna: The Journal of Internal Medicine
• Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation#839578ClinicalTrials.gov
• Quality of Life, Symptoms and Treatment Satisfaction in Adult Patients With Relapsed and/or Refractory Multiple Myeloma, Receiving Ixazomib (Ninlaro®) in Combination With Lenalidomide and Dexamethasone in a Real World Setting: Pilot Study#840085ClinicalTrials.gov
• A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma#900944ClinicalTrials.gov
• Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma#801755ClinicalTrials.gov
• Front-line treatment approaches in multiple myeloma: real-world data from a community-based oncology network.#159836NCBI PubMed Central
• Comparison of outcomes by race among a population-based matched sample of multiple myeloma patients.#221290NCBI PubMed Central
• Single-cell profiling uncovers extracellular vesicle-associated malignant plasma cell subpopulations driving multiple myeloma progression.#415411NCBI PubMed Central
• Association between diabetic control and progression of monoclonal gammopathy of undetermined significance to multiple myeloma.#449825NCBI PubMed Central
• Racial differences in multiple myeloma survival: Associations with stem cell transplantation, insurance, and Medicaid expansion.#610597NCBI PubMed Central
• COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies#633750ClinicalTrials.gov
• CD200 is a potent new growth factor in Multiple Myeloma dependent on IGF1 receptor signaling.#662758NCBI PubMed Central